GE to sell biopharma unit to Danaher for $21.4 billion

General Electric (GE) will sell its biopharma business, which generated $3 billion in revenues for the conglomerate last year, to Danaher in a $21.4 billion deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GE Healthcare partners with Vanderbilt University to create AI apps

17 January 2019 US-based medical technology company GE Healthcare has entered into a five-year partnership with Vanderbilt University Medical Center to develop cancer immunotherapies using artificial intelligence.

Americas

GE Healthcare files patent lawsuit against Bio-Rad

5 December 2018 American conglomerate GE Healthcare last week filed a lawsuit against California-based life sciences company Bio-Rad Laboratories on four counts of patent infringement.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

GE to sell biopharma unit to Danaher for $21.4 billion

More on this story

Editor's picks

Editor's picks

More features